Clinical Research Article
Effect of day therapy of sclerotherapy on 132 patients with hamangioma and vascular malformation
Chenzi Yang, Ming Cheng, Xiaping Zhang, Dingxiao Liu, Jianping Zhong, Le Xiao, Chang Shu
Published 2023-05-31
Cite as Chin J Vasc Surg, 2023, 08(2): 210-216. DOI: 10.3760/cma.j.cn101411-20230111-00002
Abstract
ObjectiveTo study the effectiveness and safety of day therapy of sclerotherapy (ST) on patients with hemangioma and vascular malformation.
MethodsClinical data of 132 patients with hemangioma and vascular malformation on the day ward of the Department of Vascular Surgery, The Second Xiangya Hospital of Central South University between May 2021 and January 2022 were retrospectively analyzed, including 55 males and 77 females. There were 36 cases of hemangioma, 78 cases of venous malformation, 7 cases of arteriovenous malformation, 2 cases of lymphatic malformation, 4 cases of capillary malformation, and 5 others. The general information, treatment condition, and complications of different lesion types were summarized.
ResultsA total of 275 injections were finished among the 132 patients, with (2.1±1.4) injections per person. The number of single treatments was 1-9 times. The 1% polidocanol (POL) dosage for injection was 176 pieces, and 3% POL was 111 pieces with single injection of (5.3±3.4) ml. There were 185 times of direct injection, and single injection of POL foam was (4.0±2.8) ml; 90 times of ultrasound-guided injection, and single injection was (7.9±3.2) ml. The difference in injection dose between the two injection methods was statistically significant. (t=10.05, P<0.001). 1% POL was used 171 times while 3% POL 104 times, with single injection was (4.2±2.9) ml and (6.8±3.6) ml, respectively. The difference between the two concentrations of a single injection dose was statistically significant (t=6.938, P<0.001). The total effective rate was 92.5% (122/132), including 37.2%(49/132) of cure rate and 55.3%(73/132) of improvement rate, the ineffective rate was 3.0%(4/132) and the therapeutic effects of the remaining 4.5%(6/132) of patients can't be evaluated. The effective rate in patients with hemangioma, venous malformation, arteriovenous malformation, and lymphatic malformation was 97.2%(35/36), 93.6%(73/78), 100%(7/7) and 100%(2/2), respectively. Complications occurred in 13 patients (9.8%), of which the incidence of arteriovenous malformation was 42.9%(3/7).
ConclusionST is effective in treating hemangioma, venous malformation, and lymphatic malformation. It is safe and feasible to perform day therapy under the guidance of ultrasound.
Key words:
Hemangioma; Vascular malformation; Sclerotherapy; Ultrasound
Contributor Information
Chenzi Yang
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Ming Cheng
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Xiaping Zhang
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Dingxiao Liu
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Jianping Zhong
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Le Xiao
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
Chang Shu
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University,Vascular Disease Institute, Central South University, Changsha 410011, China
